Literature DB >> 27923219

Nonoperative Versus Operative Treatment of Displaced Ankle Fractures in Diabetics.

Andrew J Lovy1, James Dowdell1, Aakash Keswani2, Steven Koehler1, Jaehon Kim1, Steven Weinfeld1, David Joseph3.   

Abstract

BACKGROUND: Diabetes is a risk factor for complications related to displaced ankle fractures. Limited literature exists comparing complication rates in nonoperative versus operative treatment of displaced ankle fractures in diabetics. No study has highlighted the natural history of nonoperative treatment of displaced ankle fractures in diabetics.
METHODS: We retrospectively reviewed all adult ankle fractures from September 2011 through December 2014. Inclusion was limited to ambulatory adults (>18 years) with closed, displaced (widened mortise) ankle fractures with diabetes mellitus. Nonoperative treatment consisted of closed reduction and casting. Fractures were classified according to the Lauge-Hansen and AO-Weber classification systems. All operative fractures underwent open reduction internal fixation (ORIF) within 3 weeks of injury. Functional outcomes and complication rates were compared. Of 28 displaced diabetic ankle fractures, 20 were treated nonoperatively (closed reduction and casting) and 8 operatively (ORIF within 3 weeks of injury). Mean follow-up was 7 months (range 3-18 months).
RESULTS: Age, insulin-dependent diabetes, and AO type B fracture rate were similar in nonoperative and operative cohorts, but fracture dislocation rate was significantly higher among operative fractures (87.5% vs 40%; P = .04). Nonoperative treatment was associated with a 21-fold increased odds of complication compared with operative treatment (75% vs 12.5%, OR 21.0, P = .004). Complication rate following unintended ORIF for persistent nonunion or malunion in nonoperatively treated patients was significantly greater compared with immediate ORIF (100% vs 12.5%, P = .005).
CONCLUSION: Nonoperative treatment of displaced diabetic ankle fractures was associated with unacceptably high complication rates when compared to operative treatment. LEVEL OF EVIDENCE: Level III, retrospective comparative series.

Entities:  

Keywords:  Charcot; ankle; complications; diabetes; displaced; fracture; nonoperative; operative

Mesh:

Year:  2016        PMID: 27923219     DOI: 10.1177/1071100716678796

Source DB:  PubMed          Journal:  Foot Ankle Int        ISSN: 1071-1007            Impact factor:   2.827


  7 in total

Review 1.  Special Considerations in the Management of Diabetic Ankle Fractures.

Authors:  Jeffrey M Manway; Cody D Blazek; Patrick R Burns
Journal:  Curr Rev Musculoskelet Med       Date:  2018-09

2.  Surgical timing for torsional ankle fractures is not associated with post-operative complications in patients with type II diabetes mellitus.

Authors:  Andrew P Konopitski; Ajith Malige; William Rodriguez; Chinenye O Nwachuku
Journal:  Arch Orthop Trauma Surg       Date:  2022-01-27       Impact factor: 3.067

3.  Current concepts and challenges in managing ankle fractures in the presence of diabetes: A systematic review of the literature.

Authors:  William J Nash; Thomas Hester; Joon Ha
Journal:  J Clin Orthop Trauma       Date:  2021-02-03

4.  A systematic review of ankle fracture treatment modalities in diabetic patients.

Authors:  Kshitij Manchanda; Paul Nakonezny; Ashoke K Sathy; Drew T Sanders; Adam J Starr; Dane K Wukich
Journal:  J Clin Orthop Trauma       Date:  2020-12-13

5.  Ankle Fractures in Diabetic Patients: Report of Two Cases.

Authors:  Ioannis P Galanopoulos; Panagiotis Stavlas; Sofia M Voyaki; Spyridon A Psarakis
Journal:  Cureus       Date:  2021-02-23

6.  Diabetic Kidney Disease Is Associated With Increased Complications Following Operative Management of Ankle Fractures.

Authors:  William S Polachek; Hayden P Baker; James S Dahm; Jason A Strelzow; Kelly K Hynes
Journal:  Foot Ankle Orthop       Date:  2022-07-18

Review 7.  Ankle fractures in diabetic patients.

Authors:  Nikolaos Gougoulias; Hesham Oshba; Apostolos Dimitroulias; Anthony Sakellariou; Alexander Wee
Journal:  EFORT Open Rev       Date:  2020-09-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.